Vistagen Therapeutics, Inc. (VTGN): Nasdaq/NYSE listing notice — Vistagen receives Nasdaq deficiency notice for minimum bid price non-compliance

Vistagen Therapeutics, Inc.

Received Nasdaq notice on Feb 3, 2026 for non-compliance with $1.00 minimum bid price requirement.
Stock closed below $1.00 for 30 consecutive business days; no immediate effect on listing.
Must regain compliance by Aug 3, 2026 by having $1.00 closing bid for 10 consecutive days.
May qualify for a second 180-day compliance period if other listing standards are met.
Failure to regain compliance could result in delisting from Nasdaq Capital Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Vistagen Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 3, 2026, Vistagen Therapeutics, Inc. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Staff of The Nasdaq Stock Market, LLC (“ Nasdaq ”) indicating that, based upon the closing bid price of the Company’s common stock, par value $0.001 per share (“ Common Stock ”), for the last 30 consecutive business days, the Company is not currently in compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Letter has no immediate effe

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Vistagen Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-006078

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.